MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s12886-025-03859-6

Медицинская библиотека · BMC ophthalmology · 2025

Efficacy of adalimumab in pediatric non-infectious uveitis with and without anterior segment inflammation.

Zhang Chunbo, Xue Xiaorong, Xiao Jinan, Li Qiongge, Zhai Yuyao, Chen Ying

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

This study aimed to identify the clinical characteristics of cases that is related to the response rate of adalimumab (ADA) treatment.

METHODS

A retrospective review of medical records was conducted for pediatric patients with non-infectious uveitis undergoing ADA treatment for a minimum of six months. The patients were stratified into two groups: those with anterior segment inflammation (ASI+) and those without anterior segment inflammation (ASI-). The primary outcome was treatment success rate. Secondary outcomes including best-corrected visual acuity (BCVA), inflammation parameters [anterior chamber cell (ACC), vitreous haze (VH)], retinal nerve fiber layer (RNFL) thickness, fluorescein angiography (FA) scores, as well as systemic immunosuppression therapy (IMT) and glucocorticoid load, were assessed.

RESULTS

The study included 59 patients (111 eyes), with 44 patients (83 eyes, 74.58%) falling into the ASI + group and 15 patients (28 eyes, 25.42%) in the ASI- group. The treatment success rate in the ASI + group was significantly higher than in ASI- patients (93.18% vs. 20%, p < 0.001). Following 6-month of ADA treatment in the ASI + group, there was a significant improvement in BCVA (p < 0.001), inflammation parameters (p < 0.001), reduced RNFL thickness and reduced FA scores (p < 0.001). Conversely, no significant differences were observed in BCVA, inflammation parameters, RNFL thickness and FA scores in the ASI- group. There was also a significant decrease in systemic IMT and glucocorticoid dosing, comparing baseline to the 6-month follow-up visit in both the ASI+ (p < 0.001) and ASI- groups (p < 0.05). Adverse events observed during the study period included abdominal pain, skin erythema, articular symptoms and respiratory infections.

CONCLUSION

ADA demonstrates superior efficacy in the treating pediatric non-infectious uveitis with ASI + compared to ASI-.

Для цитирования: Zhang Chunbo, Xue Xiaorong, Xiao Jinan, Li Qiongge, Zhai Yuyao, Chen Ying. Efficacy of adalimumab in pediatric non-infectious uveitis with and without anterior segment inflammation.. BMC ophthalmology. 2025. DOI: 10.1186/s12886-025-03859-6.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.